- Home
- STKS vs MIST Comparison
STKS vs MIST Comparison
Compare STKS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- MIST
- Stock Information
- Founded
- STKS 2004
- MIST 2003
- Country
- STKS United States
- MIST Canada
- Employees
- STKS N/A
- MIST N/A
- Industry
- STKS Restaurants
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- MIST Health Care
- Exchange
- STKS Nasdaq
- MIST Nasdaq
- Market Cap
- STKS 105.2M
- MIST 100.3M
- IPO Year
- STKS N/A
- MIST N/A
- Fundamental
- Price
- STKS $3.32
- MIST $1.98
- Analyst Decision
- STKS Buy
- MIST Strong Buy
- Analyst Count
- STKS 3
- MIST 3
- Target Price
- STKS $5.83
- MIST $13.00
- AVG Volume (30 Days)
- STKS 136.4K
- MIST 636.8K
- Earning Date
- STKS 03-13-2025
- MIST 11-12-2024
- Dividend Yield
- STKS N/A
- MIST N/A
- EPS Growth
- STKS N/A
- MIST N/A
- EPS
- STKS N/A
- MIST N/A
- Revenue
- STKS $541,400,000.00
- MIST N/A
- Revenue This Year
- STKS $103.81
- MIST N/A
- Revenue Next Year
- STKS $27.67
- MIST N/A
- P/E Ratio
- STKS N/A
- MIST N/A
- Revenue Growth
- STKS 63.49
- MIST N/A
- 52 Week Low
- STKS $2.68
- MIST $1.12
- 52 Week High
- STKS $6.10
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- STKS 60.29
- MIST 49.21
- Support Level
- STKS $2.75
- MIST $1.92
- Resistance Level
- STKS $3.47
- MIST $2.07
- Average True Range (ATR)
- STKS 0.18
- MIST 0.20
- MACD
- STKS 0.07
- MIST -0.03
- Stochastic Oscillator
- STKS 79.31
- MIST 9.41
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Kona Grill, ONE Hospitality, and Corporate. The company generates the vast majority of its revenue from the domestic market.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).